Harnessing regulatory T cells to establish immune tolerance

Patrick Ho; Ellen Cahir-McFarland; Jason D Fontenot; Tracey Lodie; Adel Nada; Qizhi Tang; Laurence A Turka; Jeffrey A Bluestone

doi:10.1126/scitranslmed.adm8859

Harnessing regulatory T cells to establish immune tolerance

Sci Transl Med. 2024 Mar 13;16(738):eadm8859. doi: 10.1126/scitranslmed.adm8859. Epub 2024 Mar 13.

Authors

Patrick Ho¹, Ellen Cahir-McFarland², Jason D Fontenot³, Tracey Lodie⁴, Adel Nada⁵, Qizhi Tang^{1

6

7

8}, Laurence A Turka⁹, Jeffrey A Bluestone¹⁰

Affiliations

¹ Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA.
² Abata Therapeutics, Boston, MA 02472, USA.
³ Sangamo Therapeutics, Brisbane, CA 94005, USA.
⁴ Quell Therapeutics, London W12 OBZ, UK.
⁵ GentiBio, Cambridge, MA 02140, USA.
⁶ Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
⁷ Gladstone Institute of Genomic Immunology, University of California San Francisco, San Francisco, CA 94143, USA.
⁸ Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA 94143, USA.
⁹ Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
¹⁰ Sonoma Biotherapeutics, South San Francisco, CA 09080, USA.

PMID: 38478632
DOI: 10.1126/scitranslmed.adm8859

Abstract

Engineered regulatory T (T_reg) cells have emerged as precision therapeutics aimed at inducing immune tolerance while reducing the risks associated with generalized immunosuppression. This Viewpoint highlights the opportunities and challenges for engineered T_reg cell therapies in treating autoimmune and other inflammatory diseases.

Publication types

Review

MeSH terms

Autoimmune Diseases*
Humans
Immune Tolerance
Immunosuppression Therapy
T-Lymphocytes, Regulatory*